SEC Comment Letter 0000000000-24-013874 to AIxCrypto Holdings, Inc. (AIXC)
AIxCrypto Holdings, Inc.
Date: Dec. 17, 2024 · CIK: 0001460702 · Accession: 0000000000-24-013874
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-283708
Letter
December 17, 2024 Kevin A. Richardson II Interim Chief Executive Officer Qualigen Therapeutics, Inc. 5857 Owens Avenue, Suite 300 Carlsbad, CA 92008 Re:Qualigen Therapeutics, Inc. Registration Statement on Form S-1 Filed December 9, 2024 File No. 333-283708 Dear Kevin A. Richardson II: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Doris Stacey Gama at 202-551-3188 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Ross Carmel, Esq.
Show Raw Text
December 17, 2024
Kevin A. Richardson II
Interim Chief Executive Officer
Qualigen Therapeutics, Inc.
5857 Owens Avenue, Suite 300
Carlsbad, CA 92008
Re:Qualigen Therapeutics, Inc.
Registration Statement on Form S-1
Filed December 9, 2024
File No. 333-283708
Dear Kevin A. Richardson II:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Doris Stacey Gama at 202-551-3188 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Ross Carmel, Esq.